Articles: Best practise for dealmakers by dealmakers
Best practise for dealmakers by dealmakers. Current Partnering seeks out the best articles from various sources, to keep you updated on partnering best practice.
If delegates are expected to request an appointment with another company only on the basis of the latter’s partnering information (and especially considering what the latter is not interested in), they must be given the opportunity and time to actually see and study it
We, on the side of the organisers, have always been in the position of an observer. We see what is going on during the week-long run-up to a euroPLX Meeting, and during the two days of the event itself
Better scientific understanding of drug interactions with enzymes at the molecular level has allowed some old, ‘failed’ molecules to be used for novel purposes
In only its second year, EBD Group’s partnering event for the medical technology industry, EuroMedtech, has become the premier destination for emerging innovator companies and start-ups to seek out and secure funding
The 4th edition of BIO-Europe Spring® will attract leaders from the international biotech industry to Barcelona, Spain on March 8-10, where local host BioRegion of Catalonia (Biocat) promises to surprise attendees with opportunities for projects, products and investments
An interesting study was carried out between 1990 and 2007 which discovered that the most frequently negotiated royalty rate is 5% of net sales.
As the pharmaceutical industry hurtles ever closer towards the ‘patent cliff’, Big Pharma* is busy implementing strategies to lessen the impact of the loss of patent protection on some of the industry’s biggest sellers on their collective bottom lines
One of the challenges prior to each partnering conference is the issue of other delegates asking you for a meeting to discuss an opportunity which you are not interested in
The issues discussed there also apply to collaborations. In addition, there are particular considerations that apply to collaboration agreements. This article looks at the areas specific to collaboration agreements
Whatever the economic climate, licences warrant careful drafting since they are generally long-lasting agreements. In the biotechnology arena they also have an important role for both licensors and licensees in demonstrating commercial progress
The story will sound all too familiar to you and the situation is very common, indeed. You meet dozens of people at an exhibition, a congress, or a partnering conference, exchange business cards and ideas, and mutually agree to pursue the opportunities right after the event.
Multi-disciplinary healthcare giant Abbott Laboratories has fought off competition from Nycomed to secure the $6.6 billion acquisition of Solvay's pharmaceutical business
The pharmaceutical industry is experiencing troubling times. An unprecedented number of “blockbuster” drugs are going off patent, and the lack of replacements in the pipeline is leading to near flat growth projections in major markets
The targeted information which is transferred in order to serve the intended partnering objective, is only one part of the informational interaction. The other part is an informational “by-product” which is not intended in the first place, and which is activated by communication, questions on the side, small talk. It is sometimes more valuable than the targeted message. And this is also the reason why savvy partnering veterans derive value even from one-on-one meetings whose primary purpose turns out to be a misunderstanding, or just not feasible
How businesses can convince potential business partners and investors to support them and their ideas – in just 30 minutes
In this study by Jean O. Lanjouw and Mark Schankerman, the findings show that small patentees are at a significant disadvantage in protecting their patent rights, since their greater litigation risk is not offset by more rapid resolution of their suits
In this paper, Bruno van Pottelsberghe focuses on the performance of the patent regime, the consistency of rules across countries and global governance questions concerning international cooperation among patent offices which are of major importance for competitiveness and growth
When business development executives attend a euroPLX meeting (or any other partnering conference for that matter) they experience a learning process
PanGenerika is a company that was created and registered in the Netherlands in June 2007 with the intention of easing the burden on pharmaceutical companies that want to enter the European market
This article introduces what should be considered in negotiating license agreements with pending patent application. It recommends the licensor to insert a de-escalating royalty clause and a clause regarding the “know-how” information to be protected from the uncertainty of the patent prosecution process.
This article by Katrin Hussinger analyzes the importance of patenting versus secrecy. Based on the empirical analysis of product innovating firms in German manufacturing in 2000, it finds that patents are more important than secrecy to protect the income generated from sale of new products.
In recent years, Pharma has begun to adapt its business model in response to growing industry constraints and the decline of primary-care focused blockbuster therapy. This process of change has recently been disrupted by unprecedented challenges caused by the global economic downturn and President Obama’s planned overhaul of the US healthcare system. To continue on its journey towards ‘Pharma 2.0’, Pharma needs to balance the more pressing short-term issues against the longer-term trends shaping the industry, says Datamonitor pharmaceutical strategy senior analyst Alistair Sinclair*
As a standalone company, Merck & Co. faces a tough future of declining sales. Datamonitor forecasts that the proposed merger with Schering-Plough will succeed in returning Merck to a positive sales growth outlook.
With its 40th Meeting forthcoming in June, EuroPLX® (short for European Pharma License Exchange) will enter its 15th year of facilitating pharma deals in the worldwide pharmaceutical and biotech industries.
Comprehensive list of business development events run by leading event organisers. View list
CurrentPartnering is always seeking new contributors - either freelance or publishers. Contact us now.
Do you have a view on the contents of these articles? If so, please contact us with your comments.